On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.

A string of blunders led to the value of Novo Nordisk dropping £52bn last week. Could a new weight-loss pill help it regain ...

Novo Nordisk, the Danish pharma heavyweight behind Ozempic, is feeling the squeeze as its once-booming diabetes drug sales ...

Novo Nordisk faces a sharp decline in sales of its injectable diabetes drugs, including Ozempic, due to intense competition ...

Influencer Tana Mongeau has warned against taking the weight loss drug Mounjaro after she experienced severe side effects.

Novo Nordisk saw sales growth for its diabetes and obesity care segment slow in the first half of 2025, confirming investor ...

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

Eli Lilly shares have underperformed the broader market over the past year, but Wall Street analysts remain firmly bullish in ...

U.S.-listed shares of Novo Nordisk (NVO) rose 0.5% in early premarket trading Wednesday after the Danish drugmaker reported ...

Wegovy and Zepbound - except the weight regain is worse, because of the extreme way in which these medications suppress your appetite. Yep, they’ve realised waving a patient goodbye into the sunset ...

Eli Lilly and Company is gearing up for its second quarter earnings report this Thursday, before the market opens. The pharmaceutical giant has witnessed significant revenue boosts from its ...